ViraLite: An Ultracompact HIV Viral Load Self-Testing System with Internal Quality Control

Anthony J. Politza[1], Tianyi Liu[2], Aneesh Kshirsagar[2], Ming Dong[2], Md. Ahasan Ahamed[2,6], Muhammad Asad Ullah Khalid[6], Roland Jones[3], Uttara Seshu[4], Kathryn Risher[4], Casey N. Pinto[4,5], Yusheng Zhu[3], and Weihua Guan[6*]

1. Department of Biomedical Engineering, Pennsylvania State University, University Park, PA, United States
2. Department of Electrical Engineering, Pennsylvania State University, University Park, PA, United States
3. Departments of Pathology and Laboratory Medicine and Pharmacology, Milton S. Hershey Medical Center and Pennsylvania State University College of Medicine, Hershey, PA, United States
4. Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, PA, United States
5. The Pennsylvania State University Cancer Institute, Cancer Control Program, Hershey, PA, United States
6. Department of Intelligent Systems Engineering, Indiana University, Bloomington, Indiana 47408

* Corresponding email address: guanw@iu.edu

Abstract

The availability of effective antiretroviral therapy has made HIV manageable, provided patients have consistent access to routine viral load (VL) testing. Nonetheless, access to frequent VL testing remains limited. There is a need for accessible, user-friendly testing systems that allow people living with HIV (PLHIV) to monitor their VL more frequently and empower self-management. Here, we developed ViraLite, a sample-to-answer, compact, accessible, and battery-powered system for HIV viral load monitoring. The system is built upon a probe-based RT-LAMP assay that allows for multiplexed detection and quantification. An internal quality control targeting the RNase P was incorporated to enhance the reliability of the results. A software-reconfigurable real-time sensing system empowered by machine learning and a smartphone-guided protocol was developed in tandem to analyze the multiplexed assay. We analyzed 45 clinically archived

samples using ViraLite and benchmarked our results against qRT-PCR, which showed 21 positive and 23 negative samples. Using our process control, ViraLite first identified 17 inconclusive samples that would otherwise be classified as negative. Then, ViraLite classified 14 out of 15 HIV-positive samples (93.3%) and 13 out of 13 HIV-negative samples (100%). The incorporation of RNase P as a process control increased the sensitivity of ViraLite from 66.66% to 93.33%, while maintaining a high specificity (100%). To assess the acceptance of ViraLite among PLHIV, we recruited 480 participants from online and three clinical sites to complete a survey. Over 86% of participants indicated ViraLite had benefits in convenience and privacy, on the other hand 61% of participants indicated concerns with test accuracy. The integration of compact hardware, a reliable assay, and smartphone guidance provides an accurate, easy to use system for PLHIV to self-manage their viral load and update their prescriptions frequently.

Key Words: HIV, viral load testing, multiplex, molecular probes, LAMP, internal quality control

Introduction

Advances in antiretroviral therapy (ART) have reduced HIV mortality rates and lowered transmission rates[1]. Highly active ART (HAART), a combination ART uses several individual drugs to suppress viral replication and has been widely adopted as the clinical standard[2–4]. When viral suppression is maintained below the detectable level, the risk of HIV transmission has been shown to be significantly decreased[5]. Thanks to these advances, 30 million people living with HIV (PLHIV) received treatment in 2023[6–9]. Despite advancements in treatment, HIV presents a major public health concern due to the absence of a cure[10,11]. As a result, the number of PLHIV is increasing as therapies continue to improve, creating demand for accurate and reliable testing to help PLHIV maintain viral suppression. Because of the high stigma related to HIV, VL monitoring must be highly specific, protecting the public from false positive results that lead to unnecessary psychological distress. On the other hand, VL monitoring must maintain excellent sensitivity to distinguish low copy numbers from false negatives, otherwise there is an increased risk for viral transmission through patient lifestyles. Therefore, to protect public health, viral load (VL) tests must consistently exhibit high sensitivity and specificity across diverse settings and platforms[12].

Effective viral load management hinges on chronic and precise monitoring of viral load (VL) to maintain suppression and reduce transmission[13]. Chronic monitoring is provided from regularly scheduled blood tests written every 3-6 months by the patient's physician[14]. These tests enable precise monitoring of viral load by utilizing nucleic acid tests (NAT). NATs are most compatible

with VL monitoring because they offer improved sensitivity and specificity over the faster, cheaper and more convenient alternatives, such as antigen and antibody tests[15]. NATs consist of three stages: 1. collection, 2. preparation, and 3. Analysis [16]. For this application, HIV VL monitoring, sample collection starts with a 3-5 mL blood sample, a requirement to produce the necessary amount of plasma (1-3 mL) for the next step. Viral RNA extraction can be achieved using solid-phase or liquid-phase extractions[17,18], both with similar performance, which yield isolated viral RNA in a stabilizing buffer. Last, the number of viral RNA copies is analyzed by quantitative polymerase chain reaction (qPCR) [19], the gold standard molecular test for quantifying nucleic acids due to its reliability and robustness[20]. While NATs have provided very accurate and sensitive tests for HIV VL management, the turnaround time from sample to answer can extend from several days to weeks, severely delaying prescription updates and requiring numerous visits [6,8,13,21–25].

To offer more convenient testing with shorter turnaround times, point of care devices aim to bring NAT into urgent care clinics and infectious disease centers[26]. This is accomplished by integrating all three stages of NAT into single, automated devices [27]. Several POC devices for HIV, such as the Roche Cobas Ampliprep assay and C6000 analyzer, have been developed and incorporated into clinical workflows. Similar assays and devices from Cepheid and Abbott provide comparable performance and throughput for HIV clinics [28]. These devices significantly reduce the turnaround times of traditional lab-based NAT. However, the convenience of these devices is mainly witnessed in the laboratory, providing higher throughput with less hands-on time. The sample volumes required pose a significant challenge to patient convenience and comfort, as a venous blood draw is still necessary. Therefore, these devices are not well-suited to improve patient convenience in healthcare centers.

To improve the convenience of HIV VL monitoring, several studies have focused on developing devices for at-home testing by utilizing reduced sample volumes and miniaturized electronics. Finger prick blood has been validated as a testing sample for HIV, but the small volumes involved (25-100 µl) require very high sensitivity and robust sample preparation. Successful at-home testing devices offer semi-automated workflows from finger prick blood using magnetic beads and PCR detection. However, these devices are not ideal for accessible testing due to the requirements of PCR and reliance on lab infrastructure. Loop mediated isothermal amplification (LAMP) [29] offers an alternative to PCR, offering comparable sensitivity and reaction-times[30]. Some devices have successfully implemented LAMP assays toward at-home or portable testing for a variety of infectious diseases and environmental monitoring. Our previous works [31–34] demonstrated the speed and sensitivity of LAMP for HIV VL monitoring but identified the need

103 for specific readout methods of LAMP to resolve the outstanding issues such as false positives
104 and lack of multiplexing to rival PCR [35,36]. Multiplexing is needed for at-home tests using LAMP to
105 enable internal quality control monitoring to mimic conventional PCR assays that implement
106 multiplex controls to consistently demonstrate high sensitivity and specificity[37,38], a requirement
107 for VL monitoring to safeguard public health [39]. There is an unmet need for an HIV multiplexed
108 RT-LAMP assay that uses internal quality controls for consistently high sensitivity and specificity
109 toward at-home VL monitoring for people living with HIV (PLHIV).
110 Here in this work, we present ViraLite, an ultracompact HIV VL system utilizing multiplexed
111 RT-LAMP to introduce internal quality controls for personal testing. Our device provides an easily
112 accessible, user-guided test by implementing multiplex LAMP, semi-automated electronics, and
113 smartphone assistance. The system is built upon a probe-based, multiplexable reverse-
114 transcriptase-loop-mediated isothermal amplification (RT-LAMP) assay which enables reliable
115 processing control and VL quantification. A versatile, and scalable sensing system empowered
116 by machine learning (ML) was also developed alongside the multiplex assay. From 50 µl of
117 plasma, the smartphone-guided system can detect HIV and RNase P (a process control) in a
118 multiplexed reaction. We analyzed 45 clinically archived samples using ViraLite and benchmarked
119 our results against qRT-PCR, which showed 21 positive and 23 negative samples. With our
120 process control, we identified 17 inconclusive samples that would otherwise be classified as
121 negative. Then, ViraLite classified 14 out of 15 HIV-positive samples (93.3%) and 13 out of 13
122 HIV-negative samples (100%), demonstrating the need for process control incorporation with RT-
123 LAMP assays. Using this approach improved the sensitivity of ViraLite from 66.66% to 93.33%,
124 while maintaining a high specificity (100%). To assess the usability and acceptance of ViraLite
125 among PLHIV, we recruited 480 participants from online and three clinical sites to complete a
126 survey. ViraLite showed strengths in Convenience and Privacy with over 86% of participants
127 indicating benefits in these areas. On the other hand, participants identified test Accuracy (61%)
128 as the largest concern to using our system. By integrating compact hardware, a reliable assay,
129 and smartphone guidance, ViraLite offers an accurate and user-friendly system for PLHIV to self-
130 manage their viral load and frequently update their prescriptions.
131
132 **Results**
133
134 **ViraLite Workflow**
135
136 To enable at home use, we designed and validated a portable sample-to-answer platform for
137 nucleic acid testing (**Figure *1a***). We previously validated the use of plasma separation

138 membranes[32] to collect samples and light-weight centrifuges for portable RNA extraction[40],
139 therefore enabling us to develop a fully portable system. A smartphone app will guide the user
140 through each stage: Sample Collection, RNA Extraction, and Amplification (See **Supplementary**
141 **Video S1**). Last, the extracted sample will be detected using our new multiplex RT-LAMP assay.
142 This assay uses custom designed probes to enhance the specificity of each assay for use in
143 multiplex format (**Figure *1*b-c**). ViraLite maintains a minimal packed footprint (**Figure *1*d**), and
144 introduces our next generation of fluorescence analyzer, showcasing a machine learning pipeline
145 that uses a multi-spectral color chip to empower one-pot multiplexing (**Figure *1*e**). Amplification
146 is conducted on ViraLite to provide real-time updates to the user through the Bluetooth connected
147 app.
148
149 **HIV RT-LAMP Assay with Internal Quality Control**
150
151 To create an internal quality-controlled HIV assay, we designed two probe-based LAMP
152 assays (**Supplementary Information**). We explored both assays in single-plex format before
153 migrating into a one-pot multiplex assay (**Supplementary Figure S1**). The HIV RT-LAMP assay
154 targets the Reverse-Transcriptase sub-region of the HIV genome and demonstrated a LOD of 21
155 copies (95% CI) (**Supplementary Figure S1a**). The RNase-P RT-LAMP assay targets the mRNA
156 strand 'RPP subunit p20' and demonstrated a LOD of 10 copies using a 95% confidence level
157 (**Supplementary Figure S1b**). Both assays showed very strong correlation between benchtop
158 and portable devices, suggesting suitable deployment into multiplex format (**Supplementary**
159 **Figure S2a-b**).
160 To evaluate the cross-reactivity between our RT-LAMP assays and target samples, we
161 analyzed the assay against three possible sample variations to measure specificity. We examined
162 three scenarios: HIV and RNase P positive (to simulate viral rebound), only RNase P positive (to
163 simulate a patient without viral rebound), and a No-target-control (NTC, to simulate an invalid
164 test). Each sample was tested in triplicate using a one-pot multiplex assay**.** For each of these
165 samples we found that only the appropriate target to channel relationship showed detection. For
166 example, sample 1 showed both HIV and RNase P detection (**Figure 2a**). On the other hand,
167 sample 2 showed only RNase P was detected. Sample 3 (a No Target Control) showed no
168 detection for either target, demonstrating strong specificity and no primer interactions. These
169 results were identical when tested using the ViraLite analyzer (**Supplementary Figure S3**). From
170 these results we demonstrate that our multiplex assay is robust and capable of multiplex detection
171 in clinically relevant scenarios.

172 To investigate the limit of detection (LOD) of our multiplexed LAMP, we analyzed the multiplex
173 assay with HIV-1 samples ranging from 10^5 copies down to 10 copies per reaction. As shown in
174 **Figure *2*b**, the multiplexed assay performed similarly to the single plex assay showing a
175 reasonable R^2 of 0.80 over the range of concentrations detected. The assay also showed a LOD
176 of 47 copies. These results suggest that our assay has the potential for semi-quantitative abilities
177 for HIV and can be used to process 100 µl samples which could contain concentrations as low as
178 1 cp/µl (1000 cp/mL). Next, we examined the RNase P with an identical range of RNA
179 concentrations (10^5 to 10 cp/rxn) (**Figure *2*c**). The multiplex assay showed similar performance
180 to its single-plex counterpart for RNase P showing strong linearity (R^2 = 0.82). Following a hit
181 curve analysis, we found the LOD of the multiplex assay for RNase P was 351 copies. Despite a
182 higher sensitivity than anticipated, we still expect our multiplex assay to detect RNase P from
183 plasma samples (~12 cp/µl) (**Supplementary Figure S4**). Given a finger prick sample between
184 50-100 µl, we expect between 600-1200 copies, a value well above our multiplex LOD for RNase
185 P. These results demonstrate our multiplex assay's ability to be used for the quantitative detection
186 of two targets simultaneously. Therefore, we can expect our assay to maintain high sensitivity
187 and specificity when examining clinical samples using a portable device
188
189 **Validation of Multiplex Detection**
190
191 To achieve a compact diagnostic device capable of multiplexed detection, we trained, tested,
192 and integrated a neural network that converts 8-channel fluorescence into dye concentrations
193 (FAM and HEX). Our previous study showed that a neural network worked best to clarify signal
194 from overlapping emission spectra[41] (**Supplementary Figure S5**), therefore enabling our device
195 to be battery powered, lightweight, and easy to use while maintaining a highly accurate optical
196 setup (**Figure *3*a)**[31,33,34,42,43]. To evaluate the machine learning model's accuracy, we examined
197 the analyzer's optical detection using synthetic dyes and real-time LAMP assays. We prepared
198 six concentrations of FAM and HEX dye (0, 0.2, 0.4, 0.6, 0.8, 1 µM) across 36 potential
199 combinations and collected ten data points per combination, replicated four times, and split into
200 80/20% for training and testing. We found our model performed very well demonstrating very
201 strong linearity for both FAM (R^2 = 0.994) and HEX (R^2 = 0.996) across all combinations (**Figure
202 *3*b**). These results suggest our analyzer's optical module and machine learning algorithm are well
203 suited for the multiplex analysis of real-time LAMP assays. To verify the analyzer's real-time
204 sensitivity, we conducted several amplification assays on the device. In addition, we duplicated
205 the assays to be operated in parallel on the benchtop thermal cycler. In **Figure *3*c**, we found that

206 the portable analyzer showed great agreement with the benchtop device for both HIV (r = 0.985)
207 and RNase P (r = 0.962) detection across a range of concentrations. Strong linearity and more
208 than 96% agreement with the benchtop analyzer suggests our device is highly accurate,
209 reproducible, and robust. These features make our device well suited for portable analysis of
210 multiplex assays. Further validation of our device is needed to examine its performance detecting
211 clinical plasma samples.
212
213 **Deploying ViraLite for Qualitative testing**
214
215 To validate our analyzer's qualitative performance, we examined its clinical sensitivity and
216 specificity using 45 plasma samples. Each sample was divided into two equal aliquots of 50 µl.
217 One sample was prepared and analyzed using typical laboratory protocol (centrifuge & qRT-PCR)
218 (**Figure *4*a**). The second aliquot was prepared and analyzed using our portable extraction
219 methods and analyzed using our multiplex RT-LAMP analyzer (**Figure *4*b**). These results are
220 summarized in **Figure *4*c** to provide qualitative analysis (data shown in **Supplementary Table**
221 **S1**). Our PCR results indicated 21 positive and 24 negative samples respectively. Initially, our
222 RT-LAMP results identified 15 positive and 30 negative samples, demonstrating a relatively poor
223 sensitivity (66.66%) but high specificity (100%). However, the advantage of our internal quality
224 control-based LAMP assay enables us to remove invalid tests, samples where no RNase P is
225 detected. Regardless of HIV detection, a sample will be deemed invalid if no RNase P is detected.
226 Removing these samples reduced our data set to 15 positive and 13 negative samples. As a
227 result, our RT-LAMP performance greatly improves from 66.66% sensitivity to 93.33% as we
228 identify 14 positive and 13 negative samples (**Figure *4*d**). The specificity of our assay remained
229 100%. With a sensitivity of 93.33% and 100% specificity, we demonstrate our analyzer's strong
230 qualitative ability for classifying clinical samples.
231
232 **Deploying ViraLite for Semi-Quantitative testing**
233
234 To demonstrate ViraLite's usability for semi-quantitative viral load monitoring, we classified
235 each sample using qRT-PCR and our RT-LAMP. To achieve this, we used the clinically
236 recommended threshold, 1000 cp/mL [1,20,44–47], to classify each sample using qRT-PCR C_q and
237 RT-LAMP T_p. This was established using five reference concentrations for both PCR and RT-
238 LAMP (dashed lines in **Figure *4*a-b**) to create two classes: Above and Below. The classification
239 is summarized in **Figure *4*e**. These reference concentrations showed much smaller standard

240 deviations compared to actual samples because they were tested using purified HIV RNA versus
241 extracted RNA from actual samples. Our analyzer identified 10 'above' and 18 'below' samples,
242 whereas qRT-PCR classified 8 'above' and 20 'below'. Comparing the analyzer's T_p against the
243 C_q from benchtop PCR (Figure 4f), we found our analyzer accuracy to be 86% and our overall
244 quantitative ability showed 84% agreement with the benchtop device. These results are expected
245 since our multiplex RT-LAMP assay shows an order of magnitude higher LOD than the typical
246 qRT-PCR assay (1-10 cp/rxn). We expect that further improvements to this assay could boost its
247 analytical sensitivity and therefore improve the overall accuracy for quantification. Currently, our
248 analyzer boasts 93.33% sensitivity and 100% specificity, showcasing the capability and need for
249 internal quality-controlled RT-LAMP assays. With an accuracy of 86% and 84% agreement with
250 benchtop qRT-PCR, ViraLite demonstrates a capability for semi-quantitative viral load monitoring.
251
252 **Surveying ViraLite perception among patients in HIV clinics.**
253
254 To evaluate the potential acceptance and usability of our system, we surveyed 480 patients
255 on HIV or PrEP treatment. Voluntary patients at several HIV clinics were asked to watch a short
256 video (**Supplementary Video S2**) showing the steps to operate ViraLite. After watching the video,
257 patients were asked a series of demographic and response questions. In **Figure *5*a-f** we
258 summarized the patient demographics using gender, age, income, education level, urban/rural,
259 and race. These demographics align with the 2023 U.S. Statistics for HIV, suggesting a
260 widespread and unbiased survey (**Supplementary Information**) [48]. Next, survey responses were
261 categorized by the treatment plan, HIV antiretroviral therapy or pre-exposure prophylaxis (PrEP)
262 (**Figure *5*g**). We found that 55.6% of patients were on HIV treatment and the remaining 44.4% of
263 patients were on PrEP. More than half of participants receiving HIV treatment indicated
264 Convenience, Privacy, Confidentiality, and Time Saved as their most perceived benefits (**Figure
265 *5*h**). Participants on PrEP were more interested in benefits associated with Time Saved,
266 [decreased risk of] Transmission, and Privacy. Less than 50% all participants were interested in
267 the benefits of Time to results and Cost. On the other hand, survey participants on HIV treatment
268 were most concerned with Accuracy, Guidance, and Prescription (**Figure *5*i**). Patients receiving
269 PrEP showed highest concern with Prescription [management], Misinterpretation [of results],
270 Accuracy, and Guidance. Less than half of all participants were concerned with Emotional Impact
271 [of tests/results], Record Keeping, or Cost. These results suggest that participants are deeply
272 interested in tests that bridge the gap between clinic care and at home testing; however, they are
273 concerned about the accuracy and guidance of ViraLite. Notably, the 'Cost' of the device was

neither a major benefit nor concern for people, suggesting the usefulness of at home monitoring outweighs the potential costs of ownership. Concerns over prescription management may suggest that patients are unsure how at-home testing will affect their prescription. This is an interesting topic area we will further develop alongside ViraLite. Overall, ViraLite agreement with survey feedback suggests there is high potential for immediate positive impact on patients. At the same time, the future development of ViraLite will heavily consider concerned areas as we attempt to translate this technology into patients' hands.

Discussion

To summarize, the number of PLHIV is expected to rise in the coming decade due to advancements in ART, increasing the need for effective VL management[4,14,49]. Newly developed HIV VL monitoring tests should ideally demonstrate excellent clinical sensitivity and specificity to protect both patient and public health[50,51]. This is best achieved through timely & convenient testing to encourage patients and empower self-management[28]. However, large sample volumes and lab infrastructure remain key challenges for accessible VL monitoring[26]. To address these issues, there is a need for portable, sensitive, and specific assays to bring convenient VL monitoring closer to patients.

A key innovation of our ViraLite system is its high sensitivity and specificity, achieved through our probe-based RT-LAMP assay. When analyzing 45 clinically archived plasma samples, our system demonstrated 93% clinical sensitivity and 100% clinical specificity. This was accomplished by combining two sensitive RT-LAMP assays (HIV and RNase P) into a single-pot reaction. Unlike traditional RT-LAMP, relying on turbidity or intercalating dyes[52,53], our probe-based approach detects fluorescent signal generated from a specific molecular probe, like PCR assays[54]. This approach allows us to improve clinical sensitivity by pre-classifying inconclusive samples that might otherwise be negative, using the RNase P internal quality control. In addition, the probe-based design effectively eliminates false positives, ensuring reliable VL monitoring from a portable device. A survey of potential users revealed that 86% believe it would improve testing convenience and privacy, aligning with our intended goals. However, 61% expressed concerns about test accuracy, prescription management, and guidance, indicating areas for future improvement.

A second key innovation is the development of a portable testing platform for HIV VL monitoring, enhanced by machine learning, battery-powered devices, and smartphone connectivity. A single-pot multiplex assay with two fluorophores presents a complex sensing

308 challenge for point of care devices. In our previous devices, a color sensor reads the emitted light
309 from fluorophores within a bulk assay which works well when concentrations are sufficiently
310 high[31,32,42,43]. However, multiplexing presents significantly more challenges with multiple excitation
311 sources and emission filters for detecting multi-fluorophore arrangements[41]. We addressed this
312 issue by using a multi-spectra color sensor linked to a machine learning model, which translates
313 sensor data into fluorophore concentration. This solution allows us to maintain a simple and cost-
314 effective optical setup, with all electronics housed in handheld, battery-powered devices. Real-
315 time data can be transferred wirelessly between the device and a connected smartphone for
316 update to date results.

317 ViraLite demonstrates a proof-of-concept system, offering a rapid and sensitive assay well
318 suited for resource-limited point-of-care settings. However, to fully realize a personal VL
319 management system, several improvements are needed to minimize the user interaction and
320 increase robustness. Sample preparation remains a significant challenge for compact sensitive
321 point of care devices, particularly for plasma separation from blood and extracting viral RNA is
322 challenging for small microfluidic devices aimed at patient convenience[25,55]. While previous
323 studies explored automated methods using magnetic beads and microfluidics, we chose to utilize
324 semi-automated solid-phase extraction using a portable centrifuge for its increased efficiency,
325 even at low sample concentrations[40]. Future advancements in centrifugal microfluidics could
326 enable fully integrated sample preparation, directly delivering viral RNA into multiplexed RT-LAMP.
327 Finally, our study did not incorporate lyophilization for our RT-LAMP assay. In our previous study,
328 we showed that lyophilization can be achieved without significant degradation[32]. Therefore, these
329 areas are an active area of investigation to improve device size, user interaction, and system
330 robustness.

331 The ViraLite system presented here enables highly sensitive, portable, self-testing that is
332 empowered by multiplex RT-LAMP, machine learning, and semi-automated, battery-powered
333 electronics. ViraLite demonstrates the seamless integration of sample preparation, multiplex
334 LAMP detection, and smartphone guidance for an accessible testing system for HIV VL
335 monitoring. Probe-based RT-LAMP enables multiplexed assays to rival PCR assays in detection
336 and monitoring clinical samples. Machine learning empowers ViraLite to use simple, off-the-shelf
337 optical components for accurate quantification of one-pot multiplex assays. Clinical validation with
338 clinically archived plasma samples demonstrated the real-world application of ViraLite's by
339 coupling reliable clinical data with easy to access, portable hardware. Survey participants
340 reassured us of our target demographic and gave us defined areas of improvement. In summary,
341 ViraLite introduces a viable monitoring system to translate VL management outside of clinics and

342 into accessible, comfortable locations. The conveniency of our system has the potential to rapidly
343 change the frequency of VL monitoring, offering improved ART, decreased transmission, and
344 advanced drug development.
345
346 **Materials and Methods**
347
348 **Multiplex RT-LAMP assay.** The RT-LAMP assay reaction, optimized for the detection of HIV-1,
349 involves a reaction mix with a total volume of 25 µl. The assay (shown in Supplementary Table
350 S2) contains an isothermal buffer, which includes Tris-HCl, $(NH_4)_2SO_4$, KCl, $MgSO_4$, Tween 20,
351 and dNTPs, along with *Bst*, PCR grade H_2O and $MgSO_4$ (6 mM) were also included in the reaction
352 mixture. RNA template was added in addition to primers, consisting of 0.2 µM of F3 and B3, 1.6
353 µM of FIP and BIP, and 0.8 µM of LPF and LPB. The reaction was performed at 60 ℃ for a
354 duration of 60 minutes. For the multiplexed assay, the primer concentrations were reduced to a
355 ratio of 3:2 HIV to RNase P. The HIV primer concentrations were 0.15 µM F3 and B3, 1.2 µM FIP
356 and BIP, 0.4 µM Fd and QFIP, and 0.6 µM LF and LB. The RNase P primer concentrations are
357 0.1 µM F3 and B3, 0.8 µM FIP and BIP, 0.4 µM LFP, Q and LB. All RT-LAMP primers and probes
358 are listed in Supplementary Table S3.
359
360 **qRT-PCR Assay.** The PCR HIV assay was previously validated by Palmer et al. [54] (See
361 Supplementary Table S4). The total PCR volume consisted of 25 µL: 6.25 µL of Fast Taq One-
362 Step Master Mix (Applied Biosystems, Waltham, MA), 1.5 µL of Forward and Reverse primer,
363 0.63 µL of Probe, 10 µL of extracted RNA sample, and 5.13 µL of Nuclease-free water (New
364 England Biolabs, Ipswich, MA). Analysis was conducted using a Bio-Rad C1000 Thermal Cycler
365 (Hercules, CA). Thermal Cycling was set as 50 °C for 5 min, 95 °C for 3 s, 65 °C for 30s, and
366 repeated 60×. Primers and probes were purchased from Integrated DNA Technologies (Coralville,
367 IA). Positive samples were identified and tagged with a quantitative cycle (C_q) value when the
368 background RFU reached a threshold defined as: $\mu + 3\sigma$.
369
370 **ViraLite instrumentation.** The analyzer was designed using PTC Creo software and 3D-printed
371 using a Method X printer from MakerBot system. The printed circuit boards (PCB) were designed
372 using Autodesk Eagle and manufactured by OSH Park. Laboratory personnel soldered individual
373 electronic components and the Microcontroller Unit (MCU) onto the PCB. The thermal module
374 consists of a resistive-heating element (PWR263S-20-2R00J, Digi-Key) attached to the underside
375 of the aluminum heating block using thermal compound (AATA-5G, Artic Alumina). Temperature

376 feedback is provided from within the core of the heating block by a thermistor (95C0606, Digi-
377 Key). Sustained temperature for extended periods of time was achieved using negative feedback
378 control through an N-channel power Metal-Oxide-Semiconductor Field-Effect Transistor
379 (MOSFET) (63J7707, Digi-Key). The optical module was designed using an adjustable Res
380 Cermet Trimmer (3296W, Digi-Key) for LED intensity control, a wide spectrum IC Color Sensor
381 (AS7341, Digi-Key) for optical detection, and a blue SMD LED (1497-1138-1, Digi-Key) for
382 fluorescence excitation. An I^2C multiplexer was used as the expander for the sensor. The
383 smartphone graphical user interface (GUI) software was developed using MIT App Inventor. The
384 GUI facilitates control and communication with the device via Bluetooth (**Supplementary Figure**
385 **S6a-b**). A Bill of Materials for the analyzer is included as **Supplementary Table S5**.
386
387 **Sample preparation with portable device.** Portable extractions were achieved using the Viral
388 RNA Mini kit from Qiagen. Following our previously established protocol[40], extractions were
389 performed with 50-100 µl sample, 500 µl AVL Buffer, 500 µl 95% Ethanol, 500 µl Wash Buffer I,
390 500 µl Wash Buffer II, 500 µl 95% Ethanol, and 80 µl water. During all extraction stages the
391 portable device runs at max speed (6000 rpm/ 1743 rcf.). Our smartphone app will guide a user
392 through the process of this extraction (Seen in Supplementary Video S1).
393
394 **Sample preparation with benchtop device.** Benchtop extractions were conducted according to
395 the Viral RNA Mini kit from Qiagen. Extractions were performed with 100-140 µl sample, 500 µl
396 AVL Buffer, 500 µl 95% Ethanol, 500 µl Wash Buffer I, 500 µl Wash Buffer II, 80 µl water[40]. The
397 benchtop centrifuge was set to 1 min. at 6000 rcf. for all steps except Wash Buffer II where the
398 centrifuge was operated for 3 min. at 20,000 rcf.
399
400 **Clinical Samples.** Plasma samples were collected from HIV patients treated at the Penn State
401 Hershey Medical Center following controlled standard operating procedure. Investigational
402 Review Board (IRB) approval was provided by the Pennsylvania State University
403 (STUDY00015905). The samples were de-identified and randomly selected from remnant plasma
404 batches. No identifiable data was recorded or transferred between study locations. For each test,
405 50 µl of clinical plasma sample was used.
406
407 **Survey recruitment.** Survey participants were recruited online and at the Penn State Hershey
408 Medical Center, the UPMC infectious disease center, the Penn Health Lancaster General Health
409 Comprehensive Care Center, Seattle King County HIV/STI clinics (Seattle, Washington), and the

Washington University HIV/STI clinics (St. Louis, Missouri). In total 1200 surveys were collected from all site locations. We discarded any survey which did not watch more than 30s of the video, therefore excluding 720 respondents, leaving 480 respondents. Institutional Review Board (IRB) approval was provided by the Pennsylvania State University (STUDY00024241). Participants were compensated with a $10 Amazon gift card for the successful completion of the survey.

Statistical analysis. All data processing and figure generation were completed using Python. Data is displayed as the mean of triplicates plus or minus three standard deviations, unless otherwise noted. Positive samples are classified using Time to Positive (T_p) or quantitative cycle (C_q) when RFU reaches a threshold of $\mu + 3\sigma$. LOD was calculated with 95% confidence using a logistic function fit to the hit rate for each assay. Correlation and linearity were computed using SciPy and least squares regression.

Acknowledgments

This work was partially supported by the National Institutes of Health (R61AI147419, R33AI147419), and the National Science Foundation (1912410, 2319913). Any opinions, findings, conclusions, or recommendations expressed in this work are those of the authors and should not be construed to represent any official NIH and NSF or U.S. Government determination or policy.

Declarations

The authors declare the following competing financial interest(s): A provisional patent has been filed related to the technology described herein.

Author Contributions

Anthony J. Politza: conceptualization, software, investigation, writing – original draft. **Tianyi Liu**: conceptualization, resources, writing – review & editing. **Aneesh Kshirsagar**: conceptualization, resources, writing – review & editing. **Ming Dong**: methodology, supervision, visualization, writing – review & editing. **Md. Ahasan Ahamed**: visualization, writing – review & editing. **Muhammad Asad Ullah Khalid**: supervision, writing – review & editing, project management. **Roland Jones**: resources, methodology, and investigation. **UttaraSeshu**: formal analysis, data curation, writing – review & editing. **Kathryn Risher**: formal analysis, data curation, writing – review & editing. **Casey N. Pinto**: data curation, project administration, supervision, writing – review & editing. **Yusheng Zhu**: investigation, methodology, resources, supervision. **Weihua Guan**: conceptualization, supervision, writing – review & editing, project administration, and funding acquisition.

445 **References**

446 1. Eisinger, R. W., Dieffenbach, C. W. & Fauci, A. S. HIV Viral Load and Transmissibility of HIV
447 Infection: Undetectable Equals Untransmittable. *JAMA* **321**, 451–452 (2019).
448 2. Davey, R. T. *et al.* HIV-1 and T cell dynamics after interruption of highly active antiretroviral
449 therapy (HAART) in patients with a history of sustained viral suppression. *Proc. Natl. Acad.*
450 *Sci.* **96**, 15109–15114 (1999).
451 3. Amor, A. *et al.* Seroreversion of HIV antibodies in patients with prolonged suppression of
452 viraemia under HAART. *AIDS* **20**, 1460 (2006).
453 4. J Buzón, M. *et al.* HIV-1 replication and immune dynamics are affected by raltegravir
454 intensification of HAART-suppressed subjects. *Nat. Med.* **16**, 460–465 (2010).
455 5. Tanser, F., Bärnighausen, T., Grapsa, E., Zaidi, J. & Newell, M.-L. High Coverage of ART
456 Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa.
457 *Science* **339**, 966–971 (2013).
458 6. Chamie, G., Napierala, S., Agot, K. & Thirumurthy, H. HIV testing approaches to reach the
459 first UNAIDS 95% target in sub-Saharan Africa. *Lancet HIV* **8**, e225–e236 (2021).
460 7. Stevens, W., Gous, N., Ford, N. & Scott, L. E. Feasibility of HIV point-of-care tests for
461 resource-limited settings: challenges and solutions. *BMC Med.* **12**, 1–8 (2014).
462 8. Stevens, W. S. & Marshall, T. M. Challenges in implenting HIV load testing in South Africa. *J.*
463 *Infect. Dis.* **201**, S78–S84 (2010).
464 9. Wang, H. *et al.* Estimates of global, regional, and national incidence, prevalence, and mortality
465 of HIV, 1980–2015: the Global Burden of Disease Study 2015. *Lancet HIV* **3**, e361–e387
466 (2016).
467 10. UNAIDS. Global HIV & AIDS statistics — Fact sheet.
468 https://www.unaids.org/en/resources/fact-sheet.
469 11. WHO. Summary of the Global HIV epidemic. https://www.who.int/data/gho/data/themes/hiv-
470 aids (2023).
471 12. Deeks, S. G., Overbaugh, J., Phillips, A. & Buchbinder, S. HIV infection. *Nat. Rev. Dis. Primer*
472 **1**, 1–22 (2015).
473 13. Drain, P. K. *et al.* Point-of-Care HIV Viral Load Testing: an Essential Tool for a Sustainable
474 Global HIV/AIDS Response. *Clin. Microbiol. Rev.* **32**, 10.1128/cmr.00097-18 (2019).
475 14. Peter, T. *et al.* Early antiretroviral therapy initiation: access and equity of viral load testing for
476 HIV treatment monitoring. *Lancet Infect. Dis.* **17**, e26–e29 (2017).
477 15. Niemz, A., Ferguson, T. M. & Boyle, D. S. Point-of-care nucleic acid testing for infectious
478 diseases. *Trends Biotechnol.* **29**, 240–250 (2011).

479 16. Li, M. *et al.* Nucleic Acid Tests for Clinical Translation. *Chem. Rev.* **121**, 10469–10558 (2021).
480 17. Wierucka, M. & Biziuk, M. Application of magnetic nanoparticles for magnetic solid-phase
481 extraction in preparing biological, environmental and food samples. *TrAC Trends Anal. Chem.*
482 **59**, 50–58 (2014).
483 18. Lee, S. M., Balakrishnan, H. K., Doeven, E. H., Yuan, D. & Guijt, R. M. Chemical Trends in
484 Sample Preparation for Nucleic Acid Amplification Testing (NAAT): A Review. *Biosensors* **13**,
485 980 (2023).
486 19. Piatak, M. *et al.* High Levels of HIV-1 in Plasma During All Stages of Infection Determined By
487 Competitive PCR. *Science* **259**, 1749–1754 (1993).
488 20. Saag, M. S. *et al.* HIV viral load markers in clinical practice. *Nat. Med.* **2**, 625–629 (1996).
489 21. Stevens, W., Gous, N., Ford, N. & Scott, L. E. Feasibility of HIV point-of-care tests for
490 resource-limited settings: challenges and solutions. *BMC Med.* **12**, 173 (2014).
491 22. Shafiee, H. *et al.* Emerging Technologies for Point-of-Care Management of HIV Infection.
492 *Annu. Rev. Med.* **66**, 387–405 (2015).
493 23. Schito, M. *et al.* Opportunities and Challenges for Cost-Efficient Implementation of New Point-
494 of-Care Diagnostics for HIV and Tuberculosis. *J. Infect. Dis.* **205**, S169–S180 (2012).
495 24. Pai, N. P. *et al.* Head-to-head comparison of accuracy of a rapid point-of-care HIV test with
496 oral versus whole-blood specimens: a systematic review and meta-analysis. *Lancet Infect.*
497 *Dis.* **12**, 373–380 (2012).
498 25. Jangam, S. R., Agarwal, A. K., Sur, K. & Kelso, D. M. A point-of-care PCR test for HIV-1
499 detection in resource-limitedsettings. *Biosens. Bioelectron.* **42**, 69–75 (2013).
500 26. Dorward, J., Drain, P. K. & Garrett, N. Point-of-care viral load testing and differentiated HIV
501 care. *Lancet HIV* **5**, e8–e9 (2018).
502 27. Sloma, C. R. *et al.* Comparison of the Abbott RealTime Human Immunodeficiency Virus Type
503 1 (HIV-1) Assay to the Cobas AmpliPrep/Cobas TaqMan HIV-1 Test: Workflow, Reliability,
504 and Direct Costs. *J. Clin. Microbiol.* **47**, 889–895 (2009).
505 28. Mariani, D. *et al.* The performance of a new point-of-care HIV virus load technology to identify
506 patients failing antiretroviral treatment. *J. Clin. Virol.* **122**, 104212 (2020).
507 29. Notomi, T. *et al.* Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res.* **28**, e63
508 (2000).
509 30. Tomita, N., Mori, Y., Kanda, H. & Notomi, T. Loop-mediated isothermal amplification (LAMP)
510 of gene sequences and simple visual detection of products. *Nat. Protoc.* **3**, 877–882 (2008).
511 31. Liu, T. *et al.* Fingerpick Blood-Based Nucleic Acid Testing on A USB Interfaced Device
512 towards HIV self-testing. *Biosens Bioelectron* **209**, 114255 (2022).

513 32. Liu, T., Politza, A. J., Kshirsagar, A., Zhu, Y. & Guan, W. Compact Point-of-Care Device for
514 Self-Administered HIV Viral Load Tests from Whole Blood. *ACS Sens.* **8**, 4716–4727 (2023).
515 33. Choi, G., Prince, T., Miao, J., Cui, L. & Guan, W. Sample-to-answer palm-sized nucleic acid
516 testing device towards low-cost malaria mass screening. *Biosens. Bioelectron.* **115**, 83–90
517 (2018).
518 34. Choi, G. *et al.* A field-deployable mobile molecular diagnostic system for malaria at the point
519 of need. *Lab. Chip* **16**, 4341–4349 (2016).
520 35. Dong, M., Kshirsagar, A., Politza, A. J. & Guan, W. High Fidelity Machine-Learning-Assisted
521 False Positive Discrimination in Loop-Mediated Isothermal Amplification Using Nanopore-
522 Based Sizing and Counting. *ACS Nano* **18**, 7170–7179 (2024).
523 36. Rolando, J. C., Jue, E., Barlow, J. T. & Ismagilov, R. F. Real-time kinetics and high-resolution
524 melt curves in single-molecule digital LAMP to differentiate and study specific and non-specific
525 amplification. *Nucleic Acids Res.* **48**, e42 (2020).
526 37. Rosenstraus, M., Wang, Z., Chang, S.-Y., DeBonville, D. & Spadoro, J. P. An Internal Control
527 for Routine Diagnostic PCR: Design, Properties, and Effect on Clinical Performance. *J. Clin.*
528 *Microbiol.* **36**, 191–197 (1998).
529 38. Hoorfar, J. *et al.* Practical Considerations in Design of Internal Amplification Controls for
530 Diagnostic PCR Assays. *J. Clin. Microbiol.* **42**, 1863–1868 (2004).
531 39. Bourlet, T. *et al.* HIV-1 Load Comparison Using Four Commercial Real-Time Assays. *J. Clin.*
532 *Microbiol.* **49**, 292–297 (2020).
533 40. Politza, A. J. *et al.* Development and validation of a portable device for lab-free versatile
534 nucleic acid extraction. *BioTechniques* 1–11 (2024) doi:10.1080/07366205.2024.2427544.
535 41. Kshirsagar, A., Politza, A. J. & Guan, W. Deep Learning Enabled Universal Multiplexed
536 Fluorescence Detection for Point-of-Care Applications. *ACS Sens.* (2024)
537 doi:10.1021/acssensors.4c00860.
538 42. Kshirsagar, A. *et al.* Handheld Purification-Free Nucleic Acid Testing Device for Point-of-Need
539 Detection of Malaria from Whole Blood. *ACS Sens.* **8**, 673–683 (2023).
540 43. Tang, Z. *et al.* SLIDE: Saliva-Based SARS-CoV-2 Self-Testing with RT-LAMP in a Mobile
541 Device. *ACS Sens.* **7**, 2370–2378 (2022).
542 44. Farzadegan, H. *et al.* Sex differences in HIV-1 viral load and progression to AIDS. *The Lancet*
543 **352**, 1510–1514 (1998).
544 45. Wilson, D. P., Law, M. G., Grulich, A. E., Cooper, D. A. & Kaldor, J. M. Relation between HIV
545 viral load and infectiousness: a model-based analysis. *The Lancet* **372**, 314–320 (2008).

546 46. Phillips, A. N. *et al.* HIV Viral Load Response to Antiretroviral Therapy According to the
547 Baseline CD4 Cell Count and Viral Load. *JAMA* **286**, 2560–2567 (2001).
548 47. Calmy, A. *et al.* HIV Viral Load Monitoring in Resource-Limited Regions: Optional or
549 Necessary? *Clin. Infect. Dis.* **44**, 128–134 (2007).
550 48. HIV & AIDS Trends and U.S. Statistics Overview. *HIV.gov* https://www.hiv.gov/hiv-
551 basics/overview/data-and-trends/statistics.
552 49. Johnson, C. C. *et al.* To err is human, to correct is public health: a systematic review examining
553 poor quality testing and misdiagnosis of HIV status. *J. Int. AIDS Soc.* **20**, 21755 (2017).
554 50. Drain, P. K. *et al.* Point-of-Care HIV Viral Load Testing: an Essential Tool for a Sustainable
555 Global HIV/AIDS Response. *Clin. Microbiol. Rev.* **32**, 10.1128/cmr.00097-18 (2019).
556 51. Hayes, R. J. *et al.* Effect of Universal Testing and Treatment on HIV Incidence — HPTN 071
557 (PopART). *N. Engl. J. Med.* **381**, 207–218 (2019).
558 52. Nagamine, K., Hase, T. & Notomi, T. Accelerated reaction by loop-mediated isothermal
559 amplification using loop primers. *Mol. Cell. Probes* **16**, 223–229 (2002).
560 53. Curtis, K. A. *et al.* A multiplexed RT-LAMP assay for detection of group M HIV-1 in plasma or
561 whole blood. *J. Virol. Methods* **255**, 91–97 (2018).
562 54. Palmer, S. *et al.* New real-time reverse transcriptase-initiated PCR assay with single-copy
563 sensitivity for human immunodeficiency virus type 1 RNA in plasma. *J. Clin. Microbiol.* **41**,
564 4531–4536 (2003).
565 55. Guichet, E. *et al.* Comparison of different nucleic acid preparation methods to improve specific
566 HIV-1 RNA isolation for viral load testing on dried blood spots. *J. Virol. Methods* **251**, 75–79
567 (2018).
568

Figures and Legends



Figure 1. Demonstration of portable VL monitoring for self-management using the ViraLite protocols. a) Samples are first gathered using a plasma separation card that filters finger-prick blood and traps plasma into an absorption layer. Next, that layer is transferred to lysis buffer and RNA extraction is conducted using our lab developed portable centrifuge to process QIAamp viral RNA extractions. Last, the isolated RNA is added to our multiplex RT-LAMP assay for real-time analysis using our portable analyzer. b) The HIV-1 components of the multiplex assay target the reverse-transcriptase sub-region of the viral genome. A designed probe, using the FIP primer attached with a quencher, incorporates into the reaction as amplicons are generated and creates a change in fluorescence as a complementary fluorophore is released into the bulk assay. c) The Rnase P components of the multiplex assay targets the mRNA strand 'RPP subunit p20'. Another designed probe, using the LF primer attached with a fluorophore, incorporates into the reaction as dumbbell amplicons are generated and creates a change in fluorescence as a complementary quencher is released into the bulk assay. d) The entire test can be packaged into a vacuum sealed pouch; extractions are verified for long-term storage without cold-chain dependency. The RT-LAMP assay still necessitates refrigeration. e) Detecting our multiplex assay is accomplished through a fine integration of hardware and software. The handheld device reads excited photons (480 nm Blue LED) from the bulk assay using a multi-spectra color sensor. The multi-spectra color sensor outputs 8-channels of usable RFU that can then be converted to dye/fluorophore concentration using a trained neural network (NN). Concentrations are then displayed to users via smartphone app or a provided summary tab.



Figure 2. Validation of multiplex assay using cross-reactivity and limit of detection. a) The multiplex assay used FAM and HEX fluorophores to distinguish HIV-1 and RNase P, respectively. When both targets are present in the sample, there is exponential amplification for both FAM and HEX. For samples with only RNase P, there is only amplification detected in the HEX channel. No Target Controls (NTC) show no amplification for either FAM or HEX (HIV-1 or RNase P) . b) Amplification curves using the multiplex assay to detect HIV-1 show positive detection from 10^5 down to 47 cp/reaction. The multiplex assay shows a linear performance between HIV-1 RNA and Time to Positive (T_p). The hit rate analysis for HIV-1 demonstrated a limit of detection (LOD) of 47 copies using the multiplex assay, this was established using a 95% positive ratio or higher. c) Amplification curves using the multiplex assay to detect RNase P show positive detection from 10^5 down to 351 cp/reaction. The multiplex assay shows a linear performance between RNase P RNA and Time to Positive (T_p). The hit rate analysis for RNase P demonstrated a limit of detection (LOD) of 351 copies using the multiplex assay, this was established using a 95% positive ratio or higher.



Figure 3. Validation of hardware and software of the ViraLite analyzer. a) The ViraLite analyzer is composed of several electrical components housed within a custom, 3D printed enclosure. The 480nm excitation LEDs are located on the horizontal mainboard located underneath the structural spacer and heat block. Light from these LEDs will travel vertically upward into the heat-block where PCR tubes are located with the assay. Once excited, the assay will emit photons, those are detected using the spectral color sensor located orthogonally to the path of excitation light (light path is highlighted in red). A BLE enabled MCU is located on the bottom of the mainboard PCB and connects the analyzer's components together, monitors

internal feedback, and transmits data. b) The analyzer and machine learning software (neural network) showed excellent performance detecting increasing dye concentrations (FAM and HEX). c) Last, the analyzer showed very strong agreement with the benchtop thermal cycler for analyzing both targets (HIV-1 and Rnase P) in multiplex format over a range of concentrations (10^5 down to 10 copies).



Figure 4. Clinical demonstration of ViraLite using Sensitivity, Specificity, and Semi-quantitative viral loads. a) Amplification curves from 45 clinical samples using qRT-PCR as a benchmark. A 1000 cp/mL marker is designated as a dark grey dashed line. b) Amplification curves from 45 clinical samples, analyzed using our multiplex LAMP assay on our portable analyzer (data smoothing applied with python). A 1000 cp/mL marker is designated as a dark grey line. c) Positive vs Negative comparison of qRT-PCR vs our multiplex LAMP output, displayed for all 45 samples. Positive assays are labeled in red. Negative assays are labeled in green. Positive/Negative was established using a RFU threshold of μ+3*σ. d) Clinical sensitivity and specificity of our multiplex LAMP assay with and without an internal quality control to eliminate

invalid samples. e) Viral load classification of qRT-PCR vs our multiplex LAMP assay for 45 clinical samples. The typical clinical threshold of 1000 cp/mL was used to define Above (>1000 cp/mL) and Below (<1000 cp/mL) classifications. f) LAMP T_p vs PCR C_q for all valid samples, demonstrating a strong correlation in analysis between both methods.



Figure 5. Evaluation of survey participant feedback toward ViraLite improvements. The percentage of participants (n = 480) for each demographic: a) Gender, b) Age, c) Income, d) Highest Education level, e) Community, and f) Race. g) Patient responses indicated a 55.6% (HIV) to 44.4% (PrEP) separation between current treatments. h) Percent indication of the perceived benefits of our system from patients on either treatment (HIV – dark, PrEP – light). The highest percentage of marked benefits were Convenience, Privacy, and Confidentiality (HIV treatment).

645 i) Percent indication of the potential concerns of our system from patients on either treatment (HIV
646 – dark, PrEP – light). The highest percentage of marked concerns were Accuracy, Guidance, and
647 Prescription [management] (HIV treatment).